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Background
CRISPR gene editing technology can be used to
modify the expression of genes known to play a
role in lipid accumulation in hepatocytes.
Specifically, fatty acid transport proteins 2 and 5
(FATP2 & 5), located in the plasma membrane, are
present at increased levels in people with non1
alcoholic fatty liver disease . This experiment
aimed to reduce expression of FATP2 & 5 by using a
dead Cas9 with an appended inhibitory domain
(KRAB) that acts on the promotor region of the
gene. The mRNA expression, fatty acid assays, and
flow cytometry were used to evaluate the
efficiency of the CRISPR-Cas9 inhibitory system.

Methods
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Figure 1: mRNA expression of FATP genes
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Fatty Acid Assays

A mixture of palmitic and oleic acids in a 2:1 ratio (total
concentration 200 μM) was added to the cells and allowed to
incubate. BODIPY stain was added to highlight lipid inside the
cells.

Discussion

Although the results from mRNA expression levels
and fatty acid assays were expected, the same level
of inhibition does not seem to be observed in the
flow cytometry. Current work is aimed at
deciphering the mechanism behind why lipid
accumulation is not inhibited to the same extent,
such as possible upregulation of the uninhibited
transporter. Consequently, targeting both FATP2 & 5
in the same cell line may produce the desired
results. Additionally, other future projects include
running Seahorse metabolic analysis.
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Figure 2: Left: control, Right: inhibition of FATP2 gRNA2
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